Unparalleled Solid Tumor PDX Models
Accelerate Oncology Research with World-Class PDX Models
Over 1,500 deeply characterized TumorGraft® models with correlation to clinical outcomes to advance your preclinical drug development programs
Why Champions Oncology?
Drug development scientists have determined that patient-derived xenograft model selection can drive the success or failure of a preclinical study. It's critical to choose a partner with deeply characterized, clinically relevant PDX models. Champions is your preclinical oncology partner.
Clinically Relevant Models
Living & diverse bank of solid tumor PDX models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Diverse Bank of Solid Tumor PDX Models to Accelerate Preclinical Research
%20(100%20x%20700%20px).png "Untitled (100 x 100 px) (100 x 700 px)")
Champions' Solid Tumor PDX Models Accurately Reproduce Clinical Responses to Cancer Therapies
Our dedicated scientists at Champions work diligently on each preclinical study, to accelerate oncology research through providing the highest quality data and delivering groundbreaking therapies to patients.
What is a PDX?
A PDX or patient-derived xenograft model is an in vivo model generated by implanting a patient's tumor tissue into a highly immunodeficient mouse.
PDX models emulate the clinical and molecular heterogeneity of oncology patients and simulate the effects therapeutic intervention could have on that patient in a preclinical in vivo platform.
What are the differences between CDX vs PDX models?
CDX or Cell line-derived xenograft models are in vivo models generated by implanting immortalized cancer cell lines, while PDX or patient-derived xenograft models involve implanting a patient's tumor tissue into immunodeficient mice.
CDX models do not mimic the heterogeneity of a patient's tumor in a clinical setting whereas PDX models carry patient tumor's clinical and molecular characteristics, therefore making PDX models more reliable to predict the effects therapeutic intervention could have on patients.
What is the best way to select PDX models for my study?
Model selection is critical for completing successful preclinical in vivo studies. At Champions Oncology, we provide 1:1 expert consultation to determine the best models for your study design, by leveraging the industry's deepest molecular dataset.
Access to our full repository of tumor models (Lumin Analytics) including extensive clinical annotations, in vivo responses, molecular and pathological characteristics, and specific mutations to find your model.
How do I start a PDX study with Champions?
There are many aspects to planning and executing a successful PDX study. Champions works with you every step of the way to ensure you select the best models to test your hypothesis and choose endpoints that will lead to unparalleled insights driving decision-making.